AutoImmune Inc.
Records under this name other than patents AutoImmune Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,019,971 | Treatment of autoimmune arthritis by oral administration of collagen Formerly held Term ended Term ended Feb 1, 2017 · From the USPTO record | Term ended | Term ended Feb 1, 2017 | From the USPTO record |
| US 6,077,509 | Peptide fragments of myelin basic protein Lapsed on the fee record Ended Jun 20, 2012 · From the USPTO record | Lapsed on the fee record | Ended Jun 20, 2012 | From the USPTO record |
| US 6,039,947 | Peptides derived from immunodominant epitopes of myelin basic protein Lapsed on the fee record Ended Mar 21, 2012 · From the USPTO record | Lapsed on the fee record | Ended Mar 21, 2012 | From the USPTO record |
| US 6,036,957 | Suppression of T-cell proliferation using peptide fragments of myelin basic protein Lapsed on the fee record Ended Mar 14, 2012 · From the USPTO record | Lapsed on the fee record | Ended Mar 14, 2012 | From the USPTO record |
| US 6,645,504 | Bystander suppression of type I diabetes by oral administration of glucagon Lapsed on the fee record Ended Nov 11, 2011 · From the USPTO record | Lapsed on the fee record | Ended Nov 11, 2011 | From the USPTO record |
| US 6,703,361 | Method of treating or preventing Type 1 diabetes by oral administration of insulin Term ended Ended no later than Nov 11, 2010 · From the USPTO record | Term ended | Ended no later than Nov 11, 2010 | From the USPTO record |
| US 5,399,347 | Method of treating rheumatoid arthritis with type II collagen Formerly held Term ended Term ended no later than Mar 21, 2015 · Low confidence | Term ended | Term ended no later than Mar 21, 2015 | Low confidence |
| US 5,571,499 | Treatment of autoimmune diseases by aerosol administration of autoantigens Formerly held Term ended Term ended no later than Nov 5, 2016 · Low confidence | Term ended | Term ended no later than Nov 5, 2016 | Low confidence |
| US 5,571,500 | Treatment of autoimmune diseases through administration by inhalation of autoantigens Formerly held Term ended Term ended no later than Nov 5, 2016 · Low confidence | Term ended | Term ended no later than Nov 5, 2016 | Low confidence |
| US 5,593,698 | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides Term ended Term ended no later than Jan 14, 2017 · Low confidence | Term ended | Term ended no later than Jan 14, 2017 | Low confidence |